双相障碍患者的预期寿命与潜在寿命损失年:系统综述与Meta分析
该系统综述与Meta分析检索Embase、Medline、PsycINFO和Web of Science至2021年3月31日,纳入11项预期寿命研究(n=96 601)和13项潜在寿命损失年(YPLL)研究(n=128 989)。合并预期寿命为66.88年(95%CI 64.47-69.28),加权平均YPLL为12.89年(95%CI 12.72-13.07)。作者结论认为双相障碍与预期寿命显著缩短相关,亟需实施多层次针对性干预以缩小这一死亡率差距。
要点
- 双相障碍患者合并预期寿命为66.88年(95%CI 64.47-69.28;I²=99.9%,P<0.001)。
- 加权平均YPLL为12.89年(95%CI 12.72-13.07),自然死亡与不自然死亡分别归因5.94年和5.69年。
- 女性预期寿命70.51年高于男性64.59年,非洲地区最低;出生时估算的YPLL大于其他设定年龄。
核心结论
- 双相障碍与预期寿命显著缩短相关。
- 作者认为亟需实施多层次、针对性干预以缩小这一死亡率差距。
研究设计与样本
- 系统综述与Meta分析,检索Embase、Medline、PsycINFO和Web of Science数据库至2021年3月31日。
- 预期寿命分析纳入11项研究(n=96 601),YPLL分析纳入13项研究(n=128 989)。
- 采用随机效应模型生成合并预期寿命,YPLL汇总估计按各研究样本量加权平均值得出。
- 按性别、地理区域、研究时段、估算寿命的设定年龄和死因进行亚组分析。
- 研究注册于PROSPERO(CRD42021241705)。
主要发现
- 合并预期寿命为66.88年(95%CI 64.47-69.28;I²=99.9%,P<0.001)。
- 女性预期寿命70.51年(95%CI 68.61-72.41)高于男性64.59年(95%CI 61.16-68.03);z=2.00,P=0.003。
- 预期寿命在非洲最低;加权平均YPLL为12.89年(95%CI 12.72-13.07),在非洲最大。
- 出生时估算寿命所得YPLL多于其他设定年龄。
- 自然死亡与不自然死亡归因的YPLL分别为5.94年(95%CI 5.81-6.07)和5.69年(95%CI 5.59-5.79)。
临床怎么用
- 作者认为亟需实施多层次、针对性干预以缩小双相障碍患者的死亡率差距。
局限性
- 合并预期寿命的异质性I²=99.9%(P<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing research examining excess mortality in people with bipolar disorder using life expectancy and related measures, which quantify the disease impact on survival. However, there has been no meta-analysis to date summarising existing data on life expectancy in those with bipolar disorder. AIMS: To systematically review and quantitatively synthesise estimates of life expectancy and years of potential life lost (YPLL) in people with bipolar disorder. METHOD: We searched Embase, Medline, PsycINFO and Web of Science databases up to 31 March 2021. We generated pooled life expectancy using random-effects models, and derived YPLL summary estimate by calculating averaged values weighted by sample size of individual studies. Subgroup analyses were conducted for gender, geographical region, study period, a given age (set-age) for lifespan estimation and causes of death. The study was registered with PROSPERO (CRD42021241705). RESULTS: Eleven and 13 studies were included in the review for life expectancy (n = 96 601) and YPLL (n = 128 989), respectively. Pooled life expectancy was 66.88 years (95% CI 64.47-69.28; I2 = 99.9%, P < 0.001), was higher in women than men (70.51 (95% CI 68.61-72.41) v. 64.59 (95% CI 61.16-68.03); z = 2.00, P = 0.003) and was lowest in Africa. Weighted average YPLL was 12.89 years (95% CI 12.72-13.07), and was greatest in Africa. More YPLL was observed when lifespan was estimated at birth than at other set-age. YPLLs attributable to natural and unnatural deaths were 5.94 years (95% CI 5.81-6.07) and 5.69 years (95% CI 5.59-5.79), respectively. CONCLUSIONS: Bipolar disorder is associated with substantially shortened life expectancy. Implementation of multilevel, targeted interventions is urgently needed to reduce this mortality gap.
引用
- Chan JKN, Tong CHY, Wong CSM, et al. Life expectancy and years of potential life lost in bipolar disorder: systematic review and meta-analysis. Br J Psychiatry. 2022. PMID: 35184778. doi:10.1192/bjp.2022.19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。